Alkem Laboratories Ltd.
Nifty 200
Nifty 500
Midcap 50
Midcap 100
Midcap 150
LargeMid 250
F&O
₹5,297.00
+2.06%
Delayed · cached 15 min
Peer comparison
| Company | Price↕ | Market Cap↕ | P/E↕ | P/B↕ | ROE %↕ | ROCE %↕ | Div yield %↕ | Valuation |
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Ind L | ₹ 1,860.00 | ₹ 4.46L Cr | 40.70 | 4.99 | 16.00 | 20.50 | 0.00 | Above FV |
| Divi S Laboratories Ltd | ₹ 10,320.50 | ₹ 2.74L Cr | 93.64 | 16.35 | 16.50 | 22.00 | 0.00 | Above FV |
| Torrent Pharmaceuticals L | ₹ 4,750.00 | ₹ 1.81L Cr | 80.24 | 9.83 | 27.40 | 15.20 | 0.00 | Above FV |
| Laurus Labs Limited | ₹ 2,340.00 | ₹ 1.26L Cr | 94.43 | 20.86 | 18.30 | 17.80 | 0.09 | Above FV |
| Zydus Lifesciences Ltd | ₹ 1,197.90 | ₹ 1.19L Cr | 28.62 | 4.29 | 21.20 | 21.10 | 0.00 | Above FV |
| Dr. Reddy S Laboratories | ₹ 1,373.00 | ₹ 1.14L Cr | 40.88 | 2.96 | 11.20 | 13.00 | 0.59 | Above FV |
| Cipla Ltd | ₹ 1,411.00 | ₹ 1.14L Cr | 39.37 | 3.22 | 11.60 | 15.50 | 0.00 | Above FV |
| Mankind Pharma Limited | ₹ 2,540.00 | ₹ 1.05L Cr | 46.83 | 5.97 | 13.10 | 13.50 | 0.00 | Above FV |
| Aurobindo Pharma Ltd | ₹ 1,800.00 | ₹ 1.04L Cr | 26.07 | 2.63 | 10.10 | 12.90 | 0.17 | Above FV |
| Lupin Limited | ₹ 1,988.10 | ₹ 90,914 Cr | 17.52 | 3.78 | 28.70 | 29.90 | 0.00 | Above FV |
| Glenmark Pharmaceuticals | ₹ 2,590.00 | ₹ 73,096 Cr | 50.38 | 6.52 | 23.60 | 39.80 | 0.10 | Above FV |
| Alkem Laboratories Ltd. | ₹ 5,297.00 | ₹ 63,334 Cr | 29.36 | 4.58 | 18.90 | 21.20 | 1.02 | Above FV |
Price, market cap, P/E, P/B and dividend yield reflect the live quote (delayed, cached 15 min); ROE/ROCE from reported financials. The highlighted row is the current company. Click a column header to sort. Educational data only.
How to read the peer comparison
This table places the company beside others in the same industry on a few common measures. Comparison adds context that a single company's numbers cannot give on their own.
- Valuation multiples like P/E and P/B are most meaningful within the same industry, because different industries naturally trade at different levels. Comparing a company only to its peers is more useful than to the whole market.
- Return measures (ROE, ROCE) show how efficiently each company turns capital into profit. A company well ahead of or behind its peers here is worth understanding.
- No single column decides anything. A beginner reads the row across — valuation, returns, and size together — and treats the highlighted current company as one data point among its peers.
- Use the sortable headers to rank peers on any measure, but remember that "cheaper" or "higher" on one metric is a starting question, not an answer.
Educational only — not a recommendation to buy, sell, or hold any security.